Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Am J Ther ; 23(3): e757-65, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-24368612

RESUMEN

Defibrotide is a polydisperse mixture of single-stranded oligonucleotides with many pharmacologic properties and multiple actions on the vascular endothelium. Responses to defibrotide and other vasodepressor agents were evaluated in the pulmonary vascular bed of the cat under conditions of controlled pulmonary blood flow and constant left atrial pressure. Lobar arterial pressure was increased to a high steady level with the thromboxane A2 analog U-46619. Under increased-tone conditions, defibrotide caused dose-dependent decreases in lobar arterial pressure without altering systemic arterial and left atrial pressures. Responses to defibrotide were significantly attenuated after the administration of the cyclooxygenase inhibitor sodium meclofenamate. Responses to defibrotide were also significantly attenuated after the administration of both the adenosine 1 and 2 receptor antagonists 8-cyclopentyl-1,3-dimethylxanthine and 8-(3-chlorostyryl)caffeine. Responses to defibrotide were not altered after the administration of the vascular selective adenosine triphosphate-sensitive potassium channel blocker U-37883A, or after the administration of the nitric oxide synthase inhibitor L-N-(1-iminoethyl)-ornithine. These data show that defibrotide has significant vasodepressor activity in the pulmonary vascular bed of the cat. They also suggest that pulmonary vasodilator responses to defibrotide are partially dependent on both the activation of the cyclooxygenase enzyme and adenosine 1 and 2 receptor pathways and independent of the activation of adenosine triphosphate-sensitive potassium channels or the synthesis of nitric oxide in the pulmonary vascular bed of the cat.


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Endotelio Vascular/efectos de los fármacos , Polidesoxirribonucleótidos/farmacología , Circulación Pulmonar/efectos de los fármacos , Vasodilatadores/farmacología , Ácido 15-Hidroxi-11 alfa,9 alfa-(epoximetano)prosta-5,13-dienoico/farmacología , Adamantano/análogos & derivados , Adamantano/farmacología , Adenosina/antagonistas & inhibidores , Animales , Cafeína/análogos & derivados , Cafeína/farmacología , Gatos , Inhibidores de la Ciclooxigenasa/farmacología , Diuréticos/farmacología , Femenino , Masculino , Ácido Meclofenámico/farmacología , Morfolinas/farmacología , Óxido Nítrico , Óxido Nítrico Sintasa/antagonistas & inhibidores , Ornitina/análisis , Ornitina/farmacología , Bloqueadores de los Canales de Potasio/farmacología , Circulación Pulmonar/fisiología , Antagonistas de Receptores Purinérgicos P1/farmacología , Teofilina/análogos & derivados , Teofilina/farmacología , Resistencia Vascular , Vasoconstrictores/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA